STERIS plc STE

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.9% gain over the past six months, beating the S&P 500 by 25.5 percentage points.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

STERIS has trailed the broader market over the past year, while Wall Street analysts remain cautiously optimistic about the company’s future prospects.

STERIS stock has delivered a positive 11.2% total return over the past five years, yet current checks suggest the shares now trade close to a fair level rather than offering an obvious discount. The intrinsic value estimate from a Discounted Cash Flow (DCF) framework is slightly below the recent market price, and the broader valuation tools also lean toward STERIS being on the expensive side. Over five years, STERIS has returned 11.2%, which points to modest long term gains rather than a...

Conference appearance puts STERIS (STE) in the spotlight STERIS (STE) is drawing investor attention after confirming it will participate in the Morgan Stanley Healthcare Conference in New York on September 15, 2026, with CEO Dan Carestio scheduled to present. STERIS shares trade at US$229.65 after a small pullback in the past week, while the 90 day share price return of 9.26% points to building momentum that contrasts with a year to date share price decline of 8.15% and a 1 year total...

Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026. Dan Carestio, President and CEO of STERIS will present at 1:05 p.m. Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on STERIS’s investor relations website at www.steris-ir.com. About STERIS STERIS is a leading globa

STERIS has lagged behind the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.

Over the past six months, STERIS’s shares (currently trading at $232.53) have posted a disappointing 7.4% loss, well below the S&P 500’s 12.9% gain. This might have investors contemplating their next move.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q2, starting with STERIS (NYSE:STE).

SANFORD, N.C. — The North Carolina Railroad Co. and Norfolk Southern are making possible a new $600 million healthcare manufacturing facility in Sanford that will create at least 335 new jobs. The North Carolina Railroad Co., the state-owned 317-mile rail corridor between Morehead City and Charlotte, N.C., will spend up to $600,000 to build rail [...] Read More...

The Dublin-based company plans to relocate some existing U.S. operations to the new 600,000-square-foot campus in the coming years.